evipedia.ai
← Back

Tongkat Ali to Improve Testosterone

Evidence Review created on 09/14/2026 using AI4L / Opus 5

Also known as: Eurycoma longifolia, Longjack, Long Jack, Malaysian Ginseng, Pasak Bumi, Physta, LJ100

Motivation

Tongkat Ali is a flowering shrub of Southeast Asia whose root has been dug, dried and brewed for generations and is now sold worldwide as a standardised extract. Interest in it rests on a single claim: that it raises the body’s own testosterone instead of supplying the hormone from an outside source.

Testosterone drifts downward from roughly the fourth decade onward, and the changes attributed to that drift — low drive, flagging energy, loss of muscle and bone — sit close to the centre of how many adults experience ageing. Prescription hormone therapy corrects the shortfall directly, but it commits a person to lifelong replacement and quiets the body’s own production. A plant extract that nudges internal output, available without a prescription, occupies a different position entirely.

This review examines what controlled human research shows about Tongkat Ali and testosterone: how large and how lasting the reported hormone change is, who appears to respond and who does not, what happens to the hormones that travel with testosterone, what is known about safety and about the contents of the products themselves, and how dosing, timing and measurement have been handled in the studies that exist.

Benefits - Risks - Protocol - Conclusion

This section collects high-level overviews and expert discussions that treat Tongkat Ali and its androgen effects in substantial depth.

Content from three priority platforms could not be listed: Peter Attia’s site returns no result for this intervention, Chris Kresser’s site returns only unrelated articles, and Lifespan.io holds no article on it.

Grokipedia

Tongkat ali

Pulls taxonomy, quassinoid chemistry, trial results and safety reports into one referenced entry, which makes it useful for tracing how an individual claim connects back to its primary source.

Examine

Tongkat Ali

Grades each outcome separately, placing testosterone highest and most other outcomes well below it, and adds a safety section covering contamination, the liver-injury report and anti-doping status.

ConsumerLab

ConsumerLab has no article dedicated to Tongkat Ali. Its coverage runs to a passing mention inside a multi-ingredient answer on testosterone boosters, plus a short clinical update that answers a member question about the herb by pointing back to that same answer.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that bear on Tongkat Ali’s effect on testosterone and on its safety profile.

Both sides of the trade-off are represented: the claimed testosterone effect by the first three papers, the principal safety and product-quality concerns by the fourth. Several of the primary trials pooled in these reviews were funded or co-authored by Biotropics Malaysia, which manufactures the standardised extract used in them. On the cost side, the obvious comparator — prescription testosterone therapy — is an inexpensive generic that insurers and national health systems already reimburse, while this extract is bought out of pocket, so institutional payers have no systematic incentive to push guidelines or research funding toward either option. The structural bias running through this literature is commercial rather than institutional.

Mechanism of Action

Tongkat Ali’s activity is attributed to quassinoids — bitter plant compounds of which eurycomanone is the most abundant in the root — together with canthin-6-one alkaloids and glycosaponins, which are sugar-linked plant compounds.

In isolated rat Leydig cells, the testosterone-producing cells of the testis, eurycomanone raised testosterone output dose-dependently by inhibiting aromatase, the enzyme that converts testosterone into oestradiol, and at higher concentrations by inhibiting phosphodiesterase, the enzyme that degrades the cell’s internal cyclic AMP signal. Rat work also implicates the hypothalamic-pituitary-gonadal axis, the hormone loop running from brain to testis.

A competing reading comes from healthy young men, in whom testosterone rose while luteinising hormone (LH) and follicle-stimulating hormone (FSH), the two pituitary signals that drive the testis, did not move at all; those authors attribute the rise to adrenal steroid output through the stress axis instead. Reports also disagree about sex hormone-binding globulin (SHBG), the carrier protein that keeps testosterone in an inactive form: it fell in older adults in one study and did not change in another.

Pharmacologically, eurycomanone is poorly absorbed orally, roughly 10.5% in rats, clearing with an intravenous half-life near one hour, distributes widely outside the bloodstream, and resists breakdown by liver preparations across species. It does not strongly inhibit the major cytochrome P450 (CYP) enzymes, the liver’s main drug-processing family. No human pharmacokinetic study exists.

Historical Context & Evolution

Tongkat Ali entered use as a fever and malaria remedy. Across Malaysia, Indonesia and Indochina, root decoctions were given for intermittent fever, dysentery and recovery after childbirth, the bark served as a worm treatment and the taproot was used for high blood pressure. The aphrodisiac reputation that now dominates its marketing sat alongside these uses rather than above them, and the names Malaysian ginseng and pasak bumi date from the same period.

The turn toward hormone use came out of Malaysian government and university laboratories from the 1990s onward, which isolated the quassinoids and reported that eurycomanone increased testosterone and sperm production in rats. That laboratory work, rather than consumer demand, produced the standardised water extracts on which the clinical trials were later built, and the first human data came from a Kuala Lumpur men’s clinic treating patients with late-onset low testosterone.

Scientific opinion has since moved in both directions. Independent urology reviews now place this extract among the few marketed testosterone ingredients with any supporting human signal, a warmer reading than the blanket dismissal that testosterone boosters as a class once received. Moving the other way, a 2021 European regulatory review declined to accept the extract as safe after examining the applicant’s own genotoxicity data, and a survey of preparations sold under the same market name found mercury above the national limit. Neither verdict has closed the question.

Expected Benefits

High 🟩 🟩 🟩

Higher Serum Total Testosterone

Standardised root extracts raise circulating total testosterone, the measure used to define clinically low testosterone in men. The proposed route is greater output from the testosterone-producing cells of the testis, not hormone supplied by the product. Evidence is a meta-analysis of five randomised controlled trials (RCTs — trials assigning participants by chance to treatment or to a dummy product) plus a placebo-controlled multicentre trial in men aged 50 to 70 below the diagnostic threshold. The effect concentrates where baseline testosterone is low, and several contributing trials were manufacturer-funded.

Magnitude: Pooled standardised mean difference (SMD — an effect size expressed in standard-deviation units) of 1.352, 95% confidence interval (CI — the range in which the true value most plausibly lies) 0.565 to 2.138, in the meta-analysis of five randomised trials; in the placebo-controlled multicentre trial, 200 mg daily raised total testosterone significantly against placebo from week 4 onward.

Reduced Aging-Male Symptoms and Fatigue

Men taking the standardised water extract report fewer complaints on the Aging Males’ Symptoms scale (AMS — a validated questionnaire covering sexual, physical and psychological symptoms) and less fatigue on the Fatigue Severity Scale (FSS — a validated nine-item measure), the proposed mechanism being the testosterone rise above. A placebo-controlled multicentre trial in men aged 50 to 70 and a clinic series in late-onset low testosterone both report improvement, and a third randomised trial tracked the same scale. The clinic series was uncontrolled, and that trial paired the extract with supervised exercise.

Magnitude: AMS and FSS total scores fell significantly at every timepoint over 12 weeks at both 100 mg and 200 mg daily in the placebo-controlled multicentre trial; in an open-label clinic series the share of men scoring symptom-free rose from 10.5% to 71.7% after one month, and a six-month trial pairing the extract with concurrent training (concurrent training — aerobic and resistance exercise in the same programme) carried the same symptom scale alongside its erectile-function endpoint.

Medium 🟩 🟩

Lower Cortisol and Better Mood Under Chronic Stress

In moderately stressed adults the extract shifted the balance between the stress hormone cortisol and testosterone in saliva and improved scores on the Profile of Mood States (POMS — a validated mood questionnaire). The proposed mechanism is reduced adrenal stress-axis drive alongside higher androgen output. Evidence is one four-week placebo-controlled trial in 63 adults, co-authored by the manufacturer’s staff; a later trial in older men found cortisol fell within the treated group only, so this rests on a single controlled comparison.

Magnitude: In the four-week placebo-controlled stress trial, salivary cortisol fell 16% and salivary testosterone rose 37%, with tension down 11%, anger down 12% and confusion down 15% on the mood questionnaire.

Stronger Libido and Sexual Desire

Men taking the standardised water extract report stronger sexual desire on a validated sexual-health questionnaire, an outcome separate from erectile capacity. The proposed mechanism is the testosterone rise above acting on central drive. Evidence is one 12-week placebo-controlled trial in 109 men aged 30 to 55, co-authored by the manufacturer’s staff; a second placebo-controlled trial reporting sexual benefit paired the extract with another botanical, so it cannot isolate this one.

Magnitude: Sexual libido rose 14% by week 12 in the 12-week placebo-controlled trial of 300 mg daily in 109 men, which also recorded higher overall erectile-function scores and a gain in the physical-functioning domain of quality of life against placebo.

Low 🟩

Erectile Function ⚠️ Conflicted

Two randomised trials measured erections with the five-item International Index of Erectile Function (IIEF-5 — a validated 5-to-25 questionnaire). Pooled, they disagree sharply and show no overall benefit; only men starting from lower scores gained. Net reading: benefit appears confined to men with existing erectile impairment.

Magnitude: Pooled weighted mean difference of 0.91 IIEF-5 points, 95% CI −1.50 to 3.33 with heterogeneity of 89.5% (heterogeneity — the share of the variation between trials that reflects real disagreement rather than chance), in the meta-analysis of the two randomised trials; in the low-baseline subgroup, 2.15 points, 95% CI 1.03 to 3.27.

Muscle Strength and Physical Performance

Grip strength rose in a small uncontrolled study of active men and women aged 57 to 72, and machine-measured power rose in a resistance-training trial where training alone did the same. The placebo-controlled multicentre trial beat placebo only at the higher dose. Human data here are uncontrolled or inconsistent.

Magnitude: The direction is upward: in the placebo-controlled multicentre trial strength rose against placebo at week 12 on 200 mg but not on 100 mg, and rose within both treated groups; gains also appeared in an uncontrolled study of active seniors and a resistance-training trial in which training alone produced the same effect, and these reports give no consistent outcome figure for the size of the gain.

Semen Quality and Fertility

In men from couples with unexplained infertility, three months of the standardised extract improved semen volume, sperm concentration, motility and the share of normally shaped sperm, and some partners conceived. The series was open-label with no control group, so spontaneous improvement cannot be ruled out.

Magnitude: Among the 75 men who completed three months in the open-label infertility series, all measured semen parameters improved significantly and 11 spontaneous pregnancies followed, a rate of 14.7%.

Speculative 🟨

Bone Strength Preservation

A rat study of testosterone-deficient bone loss shows preserved bone structure and strength, and isolated bone-forming cells respond to the quassinoids. No human bone outcome has ever been measured.

Immune Marker Shifts ⭕️ Not Central to Improve Testosterone

A randomised trial in middle-aged adults reported shifts in immune cell counts, not in infections or illness. This bears on immune function rather than androgen status, and the markers are unvalidated.

Benefit-Modifying Factors

  • Baseline testosterone: The single strongest modifier. Men starting below the diagnostic threshold for low testosterone show the clearest rises and the clearest symptom change; in men already in the normal range, controlled trials show little or nothing.

  • Baseline carrier protein and oestradiol: Where sex hormone-binding globulin is high, free testosterone may move more than total testosterone does. High baseline oestradiol leaves more room for the aromatase-blocking action to matter.

  • Sex: Nearly all testosterone data come from men. In older women the one available study found free testosterone rose mainly because the carrier protein fell, and the absolute change was far smaller.

  • Age: Benefit is concentrated in men from roughly 45 to 70, the group in whom trials were run. In healthy men in their twenties, hormone changes occurred without the pituitary signals moving, and symptom benefit was not measured.

  • Pre-existing conditions: Obesity, poorly controlled diabetes, obstructive sleep apnoea and chronic psychological stress all suppress testosterone independently. Where one of these dominates, correcting it moves testosterone further than the extract does.

  • Genetic variation: No pharmacogenetic testing has been done for this extract. Variants affecting aromatase activity or carrier-protein concentration are plausible modifiers of response, but no study has stratified results by genotype.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the controlled trials run only two to twenty-four weeks and record non-serious events without incidence rates, while the documented harms are single-patient case reports and product-quality surveys rather than an adverse outcome replicated across more than one trial.

Medium 🟥 🟥

Indigestion, abdominal discomfort and constipation are the effects most often logged in trials, and restlessness or delayed sleep onset is reported when the extract is taken late in the day. The proposed mechanism for the latter is a mild stimulant action on wake-promoting pathways. The evidence base is a systematic review compiling trial adverse-event records together with safety monitoring inside a placebo-controlled multicentre trial. Events were non-serious and resolved on stopping, and no trial reported a withdrawal for them.

Magnitude: Gastrointestinal events affected 3 of 35 men on 100 mg and 3 of 35 on 200 mg, against none on placebo, in the placebo-controlled multicentre trial, lasting three to five days and clearing without treatment; the systematic review of adverse effects records the same class of events narratively without incidence rates.

Low 🟥

Acute Liver Injury

A 47-year-old man developed jaundice (yellowing of the skin), raised liver enzymes and nausea shortly after starting this supplement and improved once it was withdrawn, with other causes excluded. This is uncontrolled single-patient evidence, and whether the plant itself or an undeclared ingredient caused it is not established.

Magnitude: One published case in a man taking several supplements, with liver enzymes normalising after withdrawal; a crossover trial of 400 mg daily for six weeks found no change in liver or kidney function tests.

Heavy-Metal Contamination of Marketed Products

Analytical surveys of Malaysian preparations found mercury above the national limit in a substantial minority of products, and lead has been detected in others. The exposure evidence is indirect: these surveys measure what is in the product, not blood levels or harm in the people taking it.

Magnitude: Mercury at 0.53 to 2.35 parts per million in 26 of 100 sampled preparations against a 0.5 parts-per-million national limit, in an atomic absorption survey of products labelled tongkat ali hitam, a separate root sold under the same market name.

Undisclosed Pharmaceutical Adulteration

Products sold under this name, or containing it among several botanicals, have been recalled after analysis found undeclared erectile-dysfunction medicines or close chemical analogues, and species substitution is common. Harm is inferred from the drugs involved rather than measured in users of these specific products.

Magnitude: In a DNA-barcoding and chromatographic audit of marketed herbal products, 27% were adulterated and only 37% authenticated as the labelled species; national regulators have issued repeated recalls of sexual-enhancement products containing undeclared sildenafil or tadalafil.

New-Onset Atrial Flutter

A 71-year-old man developed atrial flutter, a fast and regular abnormal rhythm arising in the upper chambers of the heart, within days of starting the extract, with thyroid and electrolyte causes excluded. One case report only, and the authors describe causation as probable rather than established.

Magnitude: A single reported case; no controlled trial has recorded an arrhythmia signal, and cardiac rhythm has not been a routine endpoint in this literature.

Speculative 🟨

Genotoxicity Signal in Regulatory Testing

A European food-safety review found chromosome damage in cultured cells and DNA damage in rodent stomach and duodenum at 2,000 mg per kilogram. Safety was not established. The basis is laboratory and animal work only.

Rise in Red Blood Cell Mass

Raised androgen levels can thicken the blood by driving red cell production. The basis here is mechanistic only: blood counts inside the human trials showed no clinically meaningful change over the periods studied.

Prostate Growth in Androgen-Sensitive Disease

Greater androgen exposure is theoretically unwelcome where prostate tissue is androgen-driven, although isolated-cell and rat work points the other way, with quassinoids suppressing prostate cell growth. No human prostate outcome exists.

Risk-Modifying Factors

  • Baseline liver function: Existing liver disease, heavy alcohol intake or a history of supplement-related liver injury raises the stakes of the one documented hepatotoxicity case. Raised liver enzymes before starting make attribution of any later rise impossible.

  • Baseline haematocrit: Men already near or above 52% haematocrit, the share of blood volume made up of red cells, have the least headroom for any androgen-driven rise in red cell mass.

  • Sex: Women reach far lower absolute androgen levels on the same dose, so androgen-driven risks are correspondingly smaller. Pregnancy and breastfeeding are untested, and the genotoxicity finding makes that gap consequential.

  • Pre-existing conditions: Androgen-sensitive prostate disease, atrial arrhythmia, poorly controlled diabetes and untreated sleep apnoea each convert a theoretical androgen or stimulant effect into a plausible clinical one.

  • Age: Older users carry more undiagnosed prostate disease, more arrhythmia and more concurrent medication, which raises both interaction risk and the chance that an adverse event is attributed to the wrong cause.

  • Genetic variation: No variant has been linked to injury from this extract. Variation in the liver enzymes that handle co-taken medicines, and in aromatase activity, are the plausible candidates, but no study has genotyped an affected user.

Key Interactions & Contraindications

  • Beta blockers (medicines that slow the heart, such as propranolol, metoprolol, atenolol): Caution. A crossover trial found the water extract cut propranolol’s absorption, lowering total exposure 29% and peak level 42%, risking lost rate control. Doses are separated by two hours.

  • Other blood-pressure medicines (amlodipine, lisinopril, losartan): Caution. Rat artery preparations relax in response to the root extract, so additive lowering is plausible. Blood pressure is checked in the first two weeks.

  • Glucose-lowering agents (metformin, glipizide, insulin): Caution. Animal work shows glucose-lowering and improved pancreatic beta-cell function, so additive lowering and hypoglycaemia (blood sugar falling too low) are possible. Glucose is monitored on starting.

  • Prescription androgen therapy and aromatase inhibitors (testosterone gel or injection, anastrozole, enclomiphene): Caution. Overlapping targets make the combined androgen and oestrogen effect unpredictable and untested. Stacking without hormone measurement is unsupported.

  • Over-the-counter stimulants (caffeine tablets, pseudoephedrine, high-dose pre-workout blends): Caution. Additive restlessness and delayed sleep onset. Morning dosing and a capped total stimulant load are the usual mitigations.

  • Over-the-counter analgesics metabolised by the liver (paracetamol, also called acetaminophen): Caution. Given the reported liver-injury case, routine daily combination adds avoidable hepatic load. Occasional use within label dosing is the usual mitigation.

  • Other androgen-directed supplements (ashwagandha, fenugreek, Fadogia agrestis, dehydroepiandrosterone or DHEA, a hormone precursor made by the adrenal gland): Caution. Additive androgen effect with no combined safety data. Agents are introduced one at a time.

  • Supplements with additive blood-pressure or glucose effects (berberine, aged garlic extract, cinnamon extract, potassium): Caution. The same additive lowering seen with prescription agents applies. Introductions are staggered and readings monitored.

  • Anti-doping-controlled training programmes: Caution. Doping status is not a drug interaction but changes eligibility, and adulterated products are the main route to a positive test. Only batch-certified material avoids this.

Populations who should avoid Tongkat Ali:

  • Pregnancy and breastfeeding, at any dose
  • Active or suspected androgen-sensitive cancer, including prostate cancer and male breast cancer
  • Active liver disease, or liver enzymes above three times the upper limit of normal
  • Untreated erythrocytosis, meaning haematocrit above 52%
  • Unstable or recently diagnosed atrial arrhythmia
  • Children and adolescents under 18 years

Risk Mitigation Strategies

  • Low end of the range first: Protocols begin at 100 to 200 mg daily of a standardised water extract rather than 400 to 600 mg, holding four weeks before any increase. This limits gastrointestinal intolerance and sleep disruption.

  • Morning dosing: The full daily amount is taken before 10:00. This removes the restlessness and delayed sleep onset that account for most reported intolerance and keeps the measurement window for morning testosterone clean.

  • Third-party-tested material only: Selection is limited to products carrying independent testing for heavy metals and identity. This is the only practical defence against the mercury, lead and undeclared-medicine findings in marketed products.

  • Liver enzymes at 8 to 12 weeks: A single measurement of alanine aminotransferase and aspartate aminotransferase, the two enzymes that rise when liver cells are damaged, catches the one serious event on record while it is still reversible.

  • Haematocrit at 12 weeks: One full blood count detects a rising red cell fraction before it reaches the 52% threshold at which blood thickening becomes a clinical concern.

  • One agent at a time: Nothing else androgen-directed is added for at least 8 weeks. This keeps any adverse effect attributable and prevents the stacked-supplement pattern seen in the liver-injury case.

  • Separation from beta blockers and time-critical medicines: At least two hours between doses avoids the 29% loss of drug exposure documented for propranolol.

Therapeutic Protocol

  • Standard dose: 200 mg daily of a standardised water extract of the root is the regimen used in most positive trials, with 100 mg and 400 mg also studied and a 100 to 600 mg range in common practice.

  • Standardised water extract approach: The regimen that carries the trial evidence, popularised through Biotropics Malaysia’s Physta material and the Kuala Lumpur men’s clinic run by Mohd Ismail Tambi, whose late-onset hypogonadism (age-related low testosterone) series established the 200 mg dose.

  • Quassinoid-enriched and ratio-extract approach: An alternative favoured in sports supplementation, using higher-percentage eurycomanone fractions or the LJ100 material from HP Ingredients. Higher potency per milligram, but almost no controlled human data at these concentrations.

  • Raw root powder approach: The traditional preparation, still sold widely. Cheapest and closest to historical use, but eurycomanone content is unstandardised and this is where contamination and substitution findings cluster.

  • Best time of day: Morning, before 10:00. The mild stimulant effect disturbs sleep when taken late, and morning dosing aligns with the daily testosterone peak.

  • Half-life: Short. Eurycomanone cleared with a half-life near one hour in rats given it intravenously and around 0.3 hours in oral rodent work, with no human measurement.

  • Single versus split dosing: Both are used. Single morning dosing suits the sleep concern; splitting 200 to 400 mg into two morning and midday portions is the alternative where gastrointestinal upset appears.

  • Genetic considerations: No pharmacogenetic guidance exists. Variants affecting aromatase activity or carrier-protein levels are plausible dose modifiers, but no trial has genotyped participants or adjusted dose on that basis.

  • Sex-based differences: Men are the studied population. In older women, 400 mg daily raised free testosterone mainly by lowering the carrier protein; no female dose-finding work exists.

  • Age considerations: Men from 45 to 70 are the trial population and the group showing response. Above 70 there are no data, and the higher background of prostate disease and arrhythmia argues for the low end of the range.

  • Baseline biomarkers: Response tracks starting testosterone. Below roughly 300 ng/dL the trials show clear rises; within the normal range, controlled trials show little change, making a pre-dose measurement the deciding input.

  • Pre-existing conditions: Obesity, poorly controlled diabetes, sleep apnoea and chronic stress each suppress testosterone on their own and blunt the response, so they are addressed alongside rather than after.

Discontinuation & Cycling

  • Lifelong or short-term: Neither is established. The longest controlled trial ran six months, so open-ended use sits beyond the evidence; most practitioners treat it as a defined course rather than a permanent addition.

  • Withdrawal effects: None documented. No trial recorded a rebound below baseline, and no case report describes a withdrawal syndrome, though no study followed participants after stopping.

  • Tapering: Not applicable. With a short half-life and no withdrawal signal, the extract is stopped outright; there is no evidence supporting a stepped reduction.

  • Cycling for efficacy: Common in practice, untested in trials. Typical patterns run five days on and two off, or eight to twelve weeks on followed by two to four weeks off. No study has compared continuous with cycled use.

  • Reason to cycle: The argument is precautionary rather than pharmacological. Breaks limit cumulative exposure given the unresolved genotoxicity finding and give a clean window to recheck hormones off treatment.

Sourcing and Quality

  • Extract type first: A standardised water extract of the root is what the trials used. Root powder and ethanol extracts differ in quassinoid content and carry none of the clinical evidence.

  • Standardisation markers: The markers that matter are declared eurycomanone content, typically 0.8% to 1.5% in the water extracts assessed by regulators, and glycosaponin content around 40% to 65%.

  • Named standardised materials: Physta from Biotropics Malaysia carries most of the trial evidence; LJ100 from HP Ingredients is the other widely distributed standardised material. Both appear as branded ingredients inside third-party finished products.

  • National standard: Malaysian Standard MS 2409 defines the water extract specification. Products citing it have a documented identity and composition baseline rather than an unverifiable label claim.

  • Third-party testing: Essential here, not optional. The markers are independent certification of identity and heavy metals, such as an NSF or USP mark, and a batch certificate of analysis available on request.

  • Sport certification: For anyone subject to anti-doping testing, the relevant option is material certified under a sport-specific programme such as NSF Certified for Sport or Informed Sport, which screens each batch for undeclared drugs.

  • Species authentication: Adulteration and substitution are documented. Suppliers that publish DNA-based identity testing alongside chromatographic quantification address both failure modes at once.

Practical Considerations

  • Time to effect: Hormone change appears first. Total testosterone moved within two to four weeks in the controlled trials, while symptom and fatigue scores took eight to twelve weeks to separate clearly from placebo.

  • Pitfall, wrong starting point: The most common error is taking it with normal baseline testosterone. Controlled trials show little change in that group, so the money buys a measurable effect only where levels are low.

  • Pitfall, unverified product: Buying unstandardised root powder on price. This is the category in which mercury, lead, species substitution and undeclared erectile-dysfunction medicines have been found.

  • Pitfall, dose escalation: Raising the dose when nothing happens at four weeks. Trials show no added benefit above 200 to 400 mg, and higher intake moves toward the exposures behind the genotoxicity signal.

  • Regulatory status, United States: Sold as a dietary supplement, meaning the Food and Drug Administration (FDA — the United States medicines and food regulator) does not review it for effectiveness before sale and acts only after problems surface.

  • Regulatory status, European Union: Not authorised. The European Food Safety Authority (EFSA — the scientific body advising European Union food regulators) concluded in 2021 that safety was not established under any condition of use.

  • Anti-doping status: Not named on the prohibited list, but its androgen-raising claim falls near the wording that captures substances with similar biological effect, so athletes under testing use batch-certified material only.

  • Cost and access: Low. Standardised extract typically runs about 20 to 40 US dollars a month, sold without prescription online and in most supplement retailers outside the European Union.

Interaction with Foundational Habits

  • Sleep: Potentially disruptive, direction depending on timing. The mild stimulant effect delays sleep onset when taken in the evening; mouse work shows the extract promotes wakefulness during the active period while consolidating sleep during the rest period. Morning dosing before 10:00, with sleep reassessed at two weeks, is the usual handling.

  • Nutrition: Indirect and permissive. No nutrient is depleted, but zinc, magnesium and vitamin D deficiency each suppress testosterone independently and will cap any response. Correcting those comes first. Absorption of the quassinoids is poor either way, and no food-timing effect has been established.

  • Exercise: Potentiating, and the interaction with the best human evidence. The six-month trial pairing the extract with concurrent training produced its largest gains in that arm, and a resistance-training trial reported greater machine-measured strength. Training is the amplifier.

  • Stress management: Directly potentiating. The extract lowered salivary cortisol and improved tension, anger and confusion scores in moderately stressed adults, the same axis that sleep restriction and psychological load act on. Sustained stress suppresses testosterone faster than the extract raises it.

Monitoring Protocol & Defining Success

Because the intended outcome is a hormone level, the result of this intervention is directly measurable, and a baseline drawn before the first dose is what makes any later change interpretable. Blood is taken fasting between 07:00 and 10:00, when testosterone peaks, and a low first value is confirmed on a second morning, since day-to-day variation is wide. A useful baseline panel covers total and free testosterone, the carrier protein, oestradiol, luteinising hormone, a full blood count, liver enzymes and, in men from age 40, prostate-specific antigen.

The hormone panel is repeated at 4 weeks and again at 12 weeks, then every 6 to 12 months while use continues. Liver enzymes and haematocrit are rechecked once at 8 to 12 weeks and thereafter annually.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total testosterone 600–900 ng/dL The primary target of the intervention Conventional laboratories call 300–1,000 ng/dL normal; functional practice treats the lower half of that as suboptimal. Fasting, 07:00–10:00, confirmed on a second morning
Free testosterone 15–25 ng/dL The unbound fraction that reaches tissue; can move when total does not Conventional laboratories accept roughly 5–21 ng/dL, so the functional target sits in the upper part of that span. Calculated free testosterone from total, carrier protein and albumin is more reliable than most direct assays. Paired with the carrier protein below
Sex hormone-binding globulin 20–40 nmol/L The carrier protein; a fall here raises free testosterone without changing total Conventional reference ranges run far wider, roughly 10–57 nmol/L. Rises with age and with thyroid excess, falls with insulin resistance. Drawn with total testosterone in the same sample
Oestradiol (sensitive assay) 20–30 pg/mL in men Detects excess conversion of testosterone, the step the extract is proposed to block The sensitive or mass-spectrometry assay is the reliable one; standard immunoassays fail at male concentrations
Luteinising hormone 2–6 IU/L Distinguishes a testicular from a pituitary or adrenal route of any rise Drawn with the same morning sample. A rise with unchanged values here points away from the brain-to-testis loop
Haematocrit 40–48% Detects androgen-driven thickening of the blood before it becomes a clinical problem Part of a full blood count. Above 52% is the conventional action threshold; dehydration and altitude inflate the reading
Alanine and aspartate aminotransferase Both below 25 U/L The two enzymes that rise when liver cells are injured; the one serious reported event Conventional upper limits run to 40–55 U/L, well above the functional target. Intense exercise in the 48 hours before the draw distorts the result
Prostate-specific antigen Below 1.0 ng/mL under 50; below 2.0 ng/mL from 50 Baseline before any androgen-raising intervention in men from age 40 Prostate-specific antigen (PSA) is a protein made by the prostate whose level rises with prostate growth, inflammation or cancer. Ejaculation and cycling in the 48 hours before testing raise the value
Fasting glucose 75–85 mg/dL Insulin resistance suppresses testosterone and blunts any response Conventional laboratories call anything below 100 mg/dL normal, well above the functional target. Drawn fasting, ideally with fasting insulin. Relevant because animal work suggests the extract also lowers glucose

Qualitative markers are tracked alongside the panel, because a hormone rise without a felt change is a weak result:

  • Morning energy and the point in the day when it fades
  • Libido and spontaneous sexual interest, distinct from erectile capacity
  • Training performance: load moved, sessions completed, recovery between them
  • Mood stability under load, particularly irritability and mental fog
  • Sleep onset latency and the number of night wakings, watched specifically for the stimulant effect
  • Subjective sense of drive and motivation, which the validated ageing-male questionnaires capture formally

Emerging Research

  • Fertility trial in infertile men: A Phase 4 trial of Eurycoma longifolia with vitamins C and E and beta-carotene in 90 men, NCT06100432, is active and no longer recruiting. Its primary endpoints run from sperm concentration, motility and shape through to serum total testosterone.

  • Combination product for erectile dysfunction: A completed 197-participant trial of a Tongkat Ali and maca preparation, NCT05347329. Because the product pairs two botanicals, it cannot isolate this extract’s own contribution, which limits what a positive result would show.

  • Exercise versus supplement in androgen deficiency: NCT03150225 registered the four-arm, six-month trial published by Leitão et al., 2021, planned for 58 men and reported in 45. Its authors name the absence of extract-only and exercise-only comparisons as the study’s main limitation.

  • Independent replication without manufacturer funding: The decisive test is a trial run by no extract maker. The urology review by Morgado et al., 2024 sets out the population and endpoint standards such a trial would need to meet.

  • Unresolved genotoxicity question: The regulatory genotoxicity findings of Turck et al., 2021 stand unanswered. Repeat in-vivo testing at intakes close to the 200 mg human dose would settle whether DNA damage at 2,000 mg per kilogram carries any relevance.

  • Missing human pharmacokinetics: No human study has measured how much eurycomanone is absorbed or how fast it clears. The rodent work of Ahmad et al., 2018 reporting poor oral bioavailability states explicitly that its parameters cannot be extrapolated to people.

  • Preparation-specific reappraisal of androgen botanicals: A 2026 review by Sharma et al. argues evidence grades apply to characterised preparations only, and calls for active surveillance covering liver injury, cardiovascular events, contamination and drug interactions.

Conclusion

Tongkat Ali is the root of a Southeast Asian shrub, sold as a standardised extract and taken for one narrow purpose: to raise the body’s own testosterone rather than supply the hormone from outside. The pooled randomised evidence does support a rise in total testosterone, and the men in whom the change is largest are those who start out low. Alongside the hormone change, trials record fewer age-related male symptoms, less fatigue, stronger sexual desire, and a better balance between stress hormone and testosterone under sustained strain. Claims that reach further — firmer erections, more strength, better fertility — rest on evidence that is thinner, inconsistent or uncontrolled.

Two things temper this reading. Much of the supportive clinical work was funded or co-authored by the company that manufactures the leading standardised extract, and that commercial interest runs directly through the strongest trials. The independent bodies drawn on here — a European food-safety regulator, an international anti-doping organisation and a commercial reference publisher — earn no membership revenue from the answer either way, but what they add is caution rather than support: one declined to accept the extract as safe, and repeated product testing has turned up heavy metals and undeclared medicines in items sold under this name.

What remains is an effect that is real enough to measure directly, in a category where most of the uncertainty concerns what is actually in the container.

Top - Benefits - Risks - Protocol